Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction: A phase II, randomized, dose-finding study

Donald Tredway, Joan C. Schertz, Daena Bock, George Hemsey, Michael Peter Diamond

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: To determine an effective multiple-dose regimen of anastrozole compared with clomiphene citrate (CC) to induce follicular growth and ovulation in infertile women with ovulatory dysfunction. Design: Phase II, prospective, randomized, double-blind, multicenter, dose-finding, noninferiority study. Setting: Outpatient. Patient(s): Infertile women (n = 271) with ovulatory dysfunction, aged 18-40 years, with body mass index <37 kg/m2. Intervention(s): Five days of anastrozole at 1, 5, or 10 mg/d or CC at 50 mg/d. Main Outcome Measure(s): The primary endpoint was the ovulation rate (mid-luteal phase serum P level ≥10 ng/mL or clinical pregnancy) in the first treatment cycle (cycle 1). Result(s): In cycle 1 the ovulation rates for anastrozole at 1, 5, and 10 mg/d were 30.4% (n = 24), 36.8% (n = 28), and 35.9% (n = 14), respectively, compared with 64.9% (n = 50) for CC at 50 mg/d. In up to three cycles of treatment, cumulative ovulation rates did not differ between groups. No cases of ovarian hyperstimulation syndrome were reported, and both anastrozole and CC were well tolerated. Conclusion(s): In terms of ovulation rates, 5-day anastrozole at 1, 5, and 10 mg/d was less effective than CC at 50 mg/d for cycle 1 (noninferiority was not shown).

Original languageEnglish (US)
JournalFertility and sterility
Volume95
Issue number5
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Clomiphene
Ovulation
Ovarian Hyperstimulation Syndrome
Luteal Phase
Body Mass Index
Outpatients
Outcome Assessment (Health Care)
anastrozole
Pregnancy
Therapeutics
Growth
Serum

Keywords

  • Anastrozole
  • aromatase inhibitor
  • clinical pregnancy
  • clomiphene citrate
  • ovulation
  • ovulatory dysfunction

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction : A phase II, randomized, dose-finding study. / Tredway, Donald; Schertz, Joan C.; Bock, Daena; Hemsey, George; Diamond, Michael Peter.

In: Fertility and sterility, Vol. 95, No. 5, 01.01.2011.

Research output: Contribution to journalArticle

@article{c5efcf0e99f845c58b494827141d532b,
title = "Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction: A phase II, randomized, dose-finding study",
abstract = "Objective: To determine an effective multiple-dose regimen of anastrozole compared with clomiphene citrate (CC) to induce follicular growth and ovulation in infertile women with ovulatory dysfunction. Design: Phase II, prospective, randomized, double-blind, multicenter, dose-finding, noninferiority study. Setting: Outpatient. Patient(s): Infertile women (n = 271) with ovulatory dysfunction, aged 18-40 years, with body mass index <37 kg/m2. Intervention(s): Five days of anastrozole at 1, 5, or 10 mg/d or CC at 50 mg/d. Main Outcome Measure(s): The primary endpoint was the ovulation rate (mid-luteal phase serum P level ≥10 ng/mL or clinical pregnancy) in the first treatment cycle (cycle 1). Result(s): In cycle 1 the ovulation rates for anastrozole at 1, 5, and 10 mg/d were 30.4{\%} (n = 24), 36.8{\%} (n = 28), and 35.9{\%} (n = 14), respectively, compared with 64.9{\%} (n = 50) for CC at 50 mg/d. In up to three cycles of treatment, cumulative ovulation rates did not differ between groups. No cases of ovarian hyperstimulation syndrome were reported, and both anastrozole and CC were well tolerated. Conclusion(s): In terms of ovulation rates, 5-day anastrozole at 1, 5, and 10 mg/d was less effective than CC at 50 mg/d for cycle 1 (noninferiority was not shown).",
keywords = "Anastrozole, aromatase inhibitor, clinical pregnancy, clomiphene citrate, ovulation, ovulatory dysfunction",
author = "Donald Tredway and Schertz, {Joan C.} and Daena Bock and George Hemsey and Diamond, {Michael Peter}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.fertnstert.2010.12.064",
language = "English (US)",
volume = "95",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction

T2 - A phase II, randomized, dose-finding study

AU - Tredway, Donald

AU - Schertz, Joan C.

AU - Bock, Daena

AU - Hemsey, George

AU - Diamond, Michael Peter

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Objective: To determine an effective multiple-dose regimen of anastrozole compared with clomiphene citrate (CC) to induce follicular growth and ovulation in infertile women with ovulatory dysfunction. Design: Phase II, prospective, randomized, double-blind, multicenter, dose-finding, noninferiority study. Setting: Outpatient. Patient(s): Infertile women (n = 271) with ovulatory dysfunction, aged 18-40 years, with body mass index <37 kg/m2. Intervention(s): Five days of anastrozole at 1, 5, or 10 mg/d or CC at 50 mg/d. Main Outcome Measure(s): The primary endpoint was the ovulation rate (mid-luteal phase serum P level ≥10 ng/mL or clinical pregnancy) in the first treatment cycle (cycle 1). Result(s): In cycle 1 the ovulation rates for anastrozole at 1, 5, and 10 mg/d were 30.4% (n = 24), 36.8% (n = 28), and 35.9% (n = 14), respectively, compared with 64.9% (n = 50) for CC at 50 mg/d. In up to three cycles of treatment, cumulative ovulation rates did not differ between groups. No cases of ovarian hyperstimulation syndrome were reported, and both anastrozole and CC were well tolerated. Conclusion(s): In terms of ovulation rates, 5-day anastrozole at 1, 5, and 10 mg/d was less effective than CC at 50 mg/d for cycle 1 (noninferiority was not shown).

AB - Objective: To determine an effective multiple-dose regimen of anastrozole compared with clomiphene citrate (CC) to induce follicular growth and ovulation in infertile women with ovulatory dysfunction. Design: Phase II, prospective, randomized, double-blind, multicenter, dose-finding, noninferiority study. Setting: Outpatient. Patient(s): Infertile women (n = 271) with ovulatory dysfunction, aged 18-40 years, with body mass index <37 kg/m2. Intervention(s): Five days of anastrozole at 1, 5, or 10 mg/d or CC at 50 mg/d. Main Outcome Measure(s): The primary endpoint was the ovulation rate (mid-luteal phase serum P level ≥10 ng/mL or clinical pregnancy) in the first treatment cycle (cycle 1). Result(s): In cycle 1 the ovulation rates for anastrozole at 1, 5, and 10 mg/d were 30.4% (n = 24), 36.8% (n = 28), and 35.9% (n = 14), respectively, compared with 64.9% (n = 50) for CC at 50 mg/d. In up to three cycles of treatment, cumulative ovulation rates did not differ between groups. No cases of ovarian hyperstimulation syndrome were reported, and both anastrozole and CC were well tolerated. Conclusion(s): In terms of ovulation rates, 5-day anastrozole at 1, 5, and 10 mg/d was less effective than CC at 50 mg/d for cycle 1 (noninferiority was not shown).

KW - Anastrozole

KW - aromatase inhibitor

KW - clinical pregnancy

KW - clomiphene citrate

KW - ovulation

KW - ovulatory dysfunction

UR - http://www.scopus.com/inward/record.url?scp=79952903221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952903221&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2010.12.064

DO - 10.1016/j.fertnstert.2010.12.064

M3 - Article

C2 - 21300344

AN - SCOPUS:79952903221

VL - 95

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 5

ER -